RLX Technology Q3 2024 Revenue Up 20.6% to $104M Net Profit $35.62M

Nov.15.2024
RLX Technology Q3 2024 Revenue Up 20.6% to $104M Net Profit $35.62M
RLX Technology reported Q3 2024 net revenue of $104 million, a 20.6% quarter-over-quarter increase, and net profit of $35.62 million. The company attributed the growth primarily to its international expansion.

On November 15th, RELX Technology (RLX Technology Inc.) (NYSE: RLX) released its unaudited financial report for the third quarter of 2024.

 

According to the financial report, the net revenue for the third quarter of 2024 was $104.12 million, marking a 20.6% increase quarter-over-quarter and a 51.6% increase year-over-year.  

 

Under non-US GAAP, the adjusted net profit for the third quarter was $35.62 million, up 22.9% from the previous quarter and 30.0% year-over-year.  

 

The financial highlights for the third quarter of 2024 are as follows:  

 

  • Net Revenue: $104.12 million, a 20.6% increase quarter-over-quarter and a 51.6% increase year-over-year, driven primarily by the company's international expansion.  
  • Gross Profit: $28.77 million.  
  • Adjusted Net Profit: $35.62 million under non-US Generally Accepted Accounting Principles.  
  • Cash and Investments: As of September 30, 2024, RLX Technology held $2.10 billion in total cash, cash equivalents, restricted cash, short-term bank deposits, short-term investments, long-term bank deposits, and long-term investment securities.  

 

RELX Technology founder, chairman, and CEO Wang Ying said: "The company delivered strong performance once again in the third quarter, showcasing its ability to thrive amid rapidly evolving market trends and regulatory changes."  

 

"Our efficient and adaptable localization strategy has positioned us as market leaders in several countries. By working closely with local distributors and retailers, we have achieved a high level of product-market alignment."  

 

"Built on a foundation of high-quality and reliable pod products, we now offer a broader portfolio, including a diverse range of disposable and open-system products. These innovations have earned the trust of adult smokers worldwide."  

 

"As a trusted e-cigarette brand for adult smokers, we remain dedicated to developing innovative, high-quality products that align with market trends and comply with regulatory standards. Our goal is to meet the needs of global users while driving sustainable long-term growth for the company. "

 

RELX Technology's CFO, Lu Chao, said: "The company's net income in the third quarter increased by 51.6% year-over-year, reaching $104 million. This reflects the success of our internationalization strategy."

 

"Thanks to changes in our revenue structure and cost optimization measures, our gross profit margin improved by 3.2 percentage points compared to the same period last year, reaching 27.2%."

 

"Despite rapid revenue growth, we have maintained stable operating expenses under US GAAP, demonstrating strong operational leverage." 

 

"We are also pleased to return value to shareholders by distributing the second cash dividend since our IPO and continuing our stock repurchase plan." 

 

"We will actively pursue development opportunities to achieve sustainable profit growth and deliver higher returns to shareholders." 

 

Florida Governor DeSantis Expands TANF Restrictions, Blocking Welfare Benefits From Buying Tobacco and Vapes
Florida Governor DeSantis Expands TANF Restrictions, Blocking Welfare Benefits From Buying Tobacco and Vapes
Florida Governor Ron DeSantis announced an expansion of Temporary Assistance for Needy Families (TANF) restrictions that would prohibit Electronic Benefit Transfer (EBT) funds from being used to purchase tobacco and vaping products. The state will amend its TANF State Plan and submit the changes for federal approval. Florida officials said the restrictions would not affect eligibility for temporary cash assistance or the amount of benefits received, but would change how funds can be spent.
Aug.25
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Holdings Limited will acquire 100% of PT Broad Far Indonesia through two wholly owned subsidiaries for approximately RMB 90 million. The Indonesian company manufactures and sells heat-not-burn tobacco sticks and provides OEM/ODM services. The sellers are part of a related-party group controlled by Huabao International Chair and controlling shareholder Zhu Linyao. PT Broad Far Indonesia generated $4.37 million in revenue and $177,000 in profit after tax in the first half of 2026, while net assets stood at about $326,000 at June-end. An independent valuer assessed the company’s equity at approximately RMB 93.06 million. Following completion, the HNB manufacturing operation will be consolidated into Huabao International.
News
Sep.29 by 2Firsts Perspectives
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland has increased tobacco excise under Budget 2027 and announced a further rise in its E-liquid Products Tax. From Oct. 7, the tax burden on a pack of 20 cigarettes in the most popular price category increased by €1, with pro-rata increases on other tobacco products. The government plans to raise EPT from €0.50 to €0.70 per millilitre from Jan. 1, 2027, a 40% increase applying to both nicotine-containing and nicotine-free e-liquids. The tobacco duty increase is expected to raise about €63.1 million in a full year.
Regulations
Oct.09
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22